Europe PMC
Nothing Special   »   [go: up one dir, main page]

Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Dsg2-mediated c-Met activation in anaplastic thyroid cancer motility and invasion.

Author information

Affiliations

  • 1. Biotherapeutics Translational Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Republic of Korea.
      Authors
    • Lee K 1, 8
    • Lee SH 1
    • Kim W 1
    • Lee J 1
    • Park JG 1
    • Kim JS 1
    • Min JK 1
    (7 authors)
  • 2. Department of Medical Science, College of Medicine, Chungnam National University, Daejeon, Republic of Korea.
      Authors
    • Kim JT 2
    (1 author)
  • 3. Department of Endocrinology and Metabolism, College of Medicine, Chungnam National University, Daejeon, Republic of Korea.
      Authors
    • Kang YE 3
    • Kim KS 3
    (2 authors)
  • 4. Department of Internal Medicine, Chungnam National University, School of Medicine, Daejeon, Republic of Korea.
      Authors
    • Shong M 4
    (1 author)
  • 5. Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon, Republic of Korea.
      Authors
    • Lee HJ 5
    (1 author)
    • Show all (8)

ORCIDs linked to this article

Endocrine-related Cancer, 01 Nov 2020, 27(11):601-614
https://doi.org/10.1530/erc-19-0403 PMID: 33022637 

Abstract 

Anaplastic thyroid cancer (ATC) is a rapidly growing, highly metastatic cancer with limited therapeutic alternatives, thus targeted therapies need to be developed. This study aimed to examine desmoglein 2 (Dsg2) expression in ATC and its biological role and potential as a therapeutic target in ATC. Consequently, Dsg2 was downregulated or aberrantly expressed in ATC tissues. ATC patients with low Dsg2 expression levels also presented with distant metastasis. Dsg2 depletion significantly increased cell migration and invasion, with a relatively limited effect on ATC cell proliferation in vitro and increased distant metastasis in vivo. Dsg2 knockdown induced cell motility through the hepatocyte growth factor receptor (HGFR, c-Met)/Src/Rac1 signaling axis, with no alterations in the expression of EMT-related molecules. Further, specific targeting of c-Met significantly inhibited the motility of shDsg2-depleted ATC cells. Decreased membrane Dsg2 expression increased the metastatic potential of ATC cells. These results indicate that Dsg2 plays an important role in ATC cell migration and invasiveness. Therapies targeting c-Met might be effective among ATC patients with low membrane Dsg2 expression levels, indicating that the analysis of Dsg2 expression potentially provides novel insights into treatment strategies for ATC.

Full text links 

Read article at publisher's site: https://doi.org/10.1530/erc-19-0403

Citations & impact 

Impact metrics

7
Citations
Jump to Citations
10
Data citations
Jump to Data

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/91957018
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/91957018

Article citations

Go to all (7) article citations

Data 

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.